8-K: Allogene Therapeutics: Promising Interim Data in LBCL Trial

Allogene Therapeutics announced interim futility analysis from its Phase 2 ALPHA3 trial showing significantly higher MRD negativity rates with cema-cel compared to observation in first-line LBCL.

Summary

• Allogene Therapeutics reported interim futility analysis from its Phase 2 ALPHA3 trial for cemacabtagene ansegedleucel (cema-cel) in first-line large B-cell lymphoma (LBCL).
• The trial is the first randomized study in LBCL to assess MRD-guided intervention with cema-cel before relapse.
• Interim data from the first 24 randomized patients (12 cema-cel, 12 observation) showed 58.3% MRD negativity in the cema-cel arm versus 16.7% in the observation arm, a 41.6% absolute difference.
• Plasma ctDNA levels decreased by a median of 97.7% in the cema-cel arm compared to a 26.6% median increase in the observation arm at Day 45.
• Cema-cel was generally well-tolerated with no treatment-related serious adverse events, CRS, ICANS, or GvHD.
• The ALPHA3 trial is expected to enroll approximately 220 patients, with study accrual anticipated by the end of 2027.
• An interim EFS analysis is expected in mid-2027, with the primary EFS analysis in mid-2028, potentially supporting a BLA submission.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development due to strong interim efficacy signals and a favorable safety profile, although the small sample size and potential for future risks warrant cautious optimism.

Positives

• Significantly higher MRD negativity rate (58.3%) in the cema-cel arm compared to the observation arm (16.7%) in the interim futility analysis.
• Rapid and substantial decrease in plasma ctDNA levels (median 97.7%) in the cema-cel arm post-treatment.
• Cema-cel demonstrated a favorable safety profile with no treatment-related serious adverse events, CRS, ICANS, or GvHD.
• 10 out of 12 patients treated with cema-cel were managed entirely outpatient post-infusion.
• The observed MRD clearance difference of 41.6% is substantially higher than the 25-30% threshold that could translate into meaningful clinical benefit.

Negatives

• The interim analysis is based on a small sample size of 24 patients, and early data may not be predictive of later or final results.
• A numerically greater number of patients in the cema-cel arm had more aggressive disease features at baseline (e.g., Stage III-IV disease, higher IPI scores).
• Six out of 12 patients (50%) in the cema-cel arm experienced 'Other Neurologic Events' (though low grade and limited to headache, dizziness, numbness/tingling, altered taste).

Risks

• Clinical development risks, including that interim or early data may not be predictive of later or final results.
• Patient enrollment and trial execution risks.
• Uncertainties related to MRD testing, its clinical significance, and reliability, and whether MRD clearance improvements translate to meaningful clinical benefits.
• The occurrence of adverse safety events.
• Regulatory risks and uncertainties.
• Manufacturing and CMC risks.
• Reliance on third parties and licensors.
• Competitive developments and intellectual property and contractual risks.

Future Outlook

The company anticipates completing enrollment for the ALPHA3 trial by the end of 2027, with an interim EFS analysis in mid-2027 and the primary EFS analysis in mid-2028. Positive results could support a Biologics License Application (BLA) submission. The company also aims to develop and deliver allogeneic CAR T products on-demand, more reliably, and at greater scale.

Management Comments

• The Company believes these interim data provide initial support for cema-cel's potential as a novel strategy for treating high-risk patients at the end of first-line treatment.
• The ALPHA3 trial is the first randomized study in LBCL designed to assess whether minimal residual disease (MRD)-guided intervention with cema-cel before relapse can eliminate residual disease and potentially prevent recurrence.

Industry Context

StockSavvy.ai notes that the focus on MRD-guided therapy in LBCL reflects a broader industry trend towards precision medicine and optimizing treatment strategies to prevent relapse, particularly in aggressive hematological malignancies. The development of allogeneic CAR T therapies, like cema-cel, aims to address the manufacturing and accessibility challenges associated with autologous CAR T.

Comparison to Industry Standards

• The observed MRD clearance rate of 58.3% in the cema-cel arm significantly surpasses the 16.7% in the observation arm, and the 41.6% absolute difference is notably higher than the 25-30% threshold considered indicative of meaningful clinical benefit.
• Hospitalization rates for toxicity management in the cema-cel arm (two patients for unrelated events) were substantially lower than the typical 70-90% hospitalization rate for CAR T patients within 30 days, where roughly 75% are hospitalized for adverse events.

Stakeholder Impact

• Shareholders may see increased confidence in the company's lead candidate, cema-cel, and its potential for future regulatory approval and commercialization.
• Patients with LBCL, particularly those at high risk in the first-line setting, may benefit from a potentially more effective and less toxic treatment option.
• Healthcare providers and oncologists may consider cema-cel as a novel therapeutic strategy for LBCL.

Next Steps

• Continue enrollment in the ALPHA3 trial, aiming for approximately 220 patients.
• Complete study accrual by the end of 2027.
• Conduct interim EFS analysis in mid-2027.
• Conduct primary EFS analysis in mid-2028.
• Potentially submit a Biologics License Application (BLA) if results are positive.

Key Dates

Recommendation

The interim data for cema-cel in the ALPHA3 trial are promising, showing significant improvements in MRD negativity and a favorable safety profile. However, the results are based on a small sample size, and the primary endpoints (EFS, PFS, OS) are still blinded and several years away from final analysis. The company also faces inherent risks in clinical development, regulatory approval, and manufacturing. Therefore, a 'hold' recommendation is appropriate pending further data and de-risking events.

Keywords

Allogene Therapeutics, cema-cel, LBCL, CAR T, MRD, ALPHA3 trial, Oncology, Biotechnology